Eli Lilly and NVIDIA build pharma's largest AI supercomputer for drug discovery
Eli Lilly said it is building, with NVIDIA, what it calls the most powerful supercomputer owned and operated by a pharmaceutical company: the first NVIDIA DGX SuperPOD built on DGX B300 systems, with more than 1,000 Blackwell Ultra GPUs. Lilly said it will use the system to train models on millions of experiments for drug discovery, to shorten development timelines, and for medical imaging biomarkers and manufacturing. The company plans to offer some of its models to outside biotechs through its Lilly TuneLab platform. CNBC reported the system was expected to be operational in January 2026.
Why it's notable: A top drugmaker is investing in its own large-scale AI infrastructure rather than renting it, and is offering models to smaller biotechs, a sign that computation is becoming core to how new drugs reach clinical trials.